Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva expands in E Asia through JV with Korea's Handok

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries has signed an agreement to establish a new joint venture in South Korea with local firm Handok Pharmaceuticals, which will mark its first alliance in East Asian markets outside of Japan. The deal will enable Teva to tap into Korea's $14 billion pharmaceutical market through products including the multiple sclerosis drug Copaxone (glatiramer acetate injection) and its branded generics.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts